Chromium
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Chromium
Chromium: Known uses and market status in Canada
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Chromium, so there is currently no new predicted indication. No recorded uses are listed for this drug in the data behind this page. The groups below are kept for completeness.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 0 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 5 of 6; cancelled: 1) |
| Number of DINs | 6 (marketed: 5) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 00786985 | MICRO CR | Valid | |
| 02091135 | MICRO +4 REGULAR STRENGTH | Valid | |
| 02552787 | MICRO+6 REGULAR | Valid | |
| 02507587 | MICRO+6 CONCENTRATE | Valid | |
| 02091100 | MICRO PLUS 6 (PEDIATRIC) | CANCELLED POST MARKET | |
| 02497697 | ADDNUTRIV | Valid |
Safety Considerations
Please refer to the package insert for safety information.
One safety-relevant point does come from the literature. Chromium released from cobalt-chromium implants is linked to metal hypersensitivity and adverse local tissue reactions, and occupational chromium exposure is a recognized sensitizer. Hypersensitivity should therefore be considered in any clinical use for arthritis. No drug interactions were found in the data compiled for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.